Molecular Tumor Board - SMARCA4 mutation in Lung Cancer

Molecular tumor boards MTB support for clinical decision making and educationПодробнее

Molecular Tumor Board - Thoracic ARID1A and PD-L1 presentПодробнее

September 24, 2022, Revolution Cancer International Molecular Tumor Board- NOVARTIS, MET, mdm2, MSIПодробнее

August 27, 2022, Revolution Cancer International Molecular Tumor Board -GSK, SMARCA4, MTAP, NSCLCПодробнее

Molecular Tumor BoardПодробнее

Targeting SMARCA4 mutations in lung cancerПодробнее

Molecular Tumor BoardПодробнее

The Molecular Tumor BoardПодробнее

Advanced NSCLC Molecular Tumor Board Simulation Case 2Подробнее

Advanced NSCLC Molecular Tumor Board Simulation Case 1Подробнее

Molecular Tumor BoardПодробнее

Precision medicine/Molecular tumour boardПодробнее

SMARCA4Подробнее

Review of SMARCA4 (BRG1)-deficient Carcinomas Following a Malignant Pleural Effusion Specimen...Подробнее

September 10, 2022, Revolution Cancer International Molecular Tumor Board- HUTCHMED, ALK, MET, HSP90Подробнее

Cytomorphologic and Immunophenotypical Analysis of SMARCA4 (BRG1)-Deficient Non-Small Cell....Подробнее

GenomOncology Molecular Tumor BoardПодробнее

August 13, 2022, Revolution Cancer International Molecular Tumor Board (KRAS dismantled, NSCLC)Подробнее

Understanding mutations in lung cancerПодробнее